Claudia Tato-Fernández
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Claudia Tato-Fernández has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Aitana Sogorb-Esteve
Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK
2 shared publications Elina Pietilä
Turku PET Centre, Turku University Hospital, Turku, Finland; Turku PET Centre, University of Turku, Turku, Finland
2 shared publicationsHenrik Zetterberg
2 shared publications- Julia R. Bacci
Department of Epidemiology and Prevention Wake Forest University School of Medicine Winston‐Salem North Carolina USA
2 shared publications Kaj Blennow
2 shared publications- Laura Linnea Ekblad
Turku PET Centre, University Hospital of Turku, Turku, Finland
2 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Elsevier in SSRN Electronic Journal
An increase in [11C]PBR28-PET is associated with an increase in amyloid-PET during a 5-year follow-up in older adults without dementia
Neuroinflammation seems to play an important role in the pathological process of Alzheimer’s disease (AD). We hypothesized that neuroinflammation is associated with beta-amyloid (Aβ) accumulation longitudinally in preclinical AD. We performed a 5-year follow-up study with TSPO positron emission tomography (PET) and Aβ PET both at baseline and at follow-up. Altogether 40 healthy older adults without dementia or cognitive impairment at baseline (median age at follow-up 74.8 (interquartile range 73.4 to 77.2; 55% women; 50% APOEε4 carriers) were examined in 2014-2016 and 2019-2021 with [11C]PBR28-PET to measure neuroinflammation and [11C]PiB-PET to measure Aβ. [11C]PBR28 and [11C]PiB standardized uptake value ratios (SUVr) were quantified for a cortical composite region using cerebellar grey matter as the reference region. Associations between [11C]PBR28 and [11C]PiB SUVr at baseline and follow-up, and the change in [11C]PBR28 and [11C]PiB SUVr during the follow-up were analysed with linear models adjusted for age, sex and TSPO genotype. The analyses were also stratified by baseline Aβ-positivity (cut-off for positivity [11C]PiB SUVR=1.5). An increase in neuroinflammation ([11C]PBR28 SUVr) was associated with an increase in Aβ accumulation during the 5-year follow-up in the total study population (β=2.95, P=0.002), and in Aβ positive (β=2.89, P=0.04) and negative (β=1.71, P=0.04) individuals. Baseline neuroinflammation did not predict follow-up Aβ binding (β=0.74, P=0.71), or the change in Aβ accumulation during the follow-up (β=0.35, P=0.74) in the total study population. Our results suggest that neuroinflammation associated with Aβ accumulation in older individuals regardless of their Aβ status and that neuroinflammation may drive Aβ accumulation in aging.
- 25 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAn increase in [11C]PBR28-PET is associated with an increase in amyloid-PET during a 5-year follow-up in older adults without dementia
Neuroinflammation seems to play an important role in the pathological process of Alzheimer’s disease (AD). We hypothesized that neuroinflammation is associated with beta-amyloid (Aβ) accumulation longitudinally in preclinical AD. We performed a 5-year follow-up study with TSPO positron emission tomography (PET) and Aβ PET both at baseline and at follow-up. Altogether 40 healthy older adults without dementia or cognitive impairment at baseline (median age at follow-up 74.8 (interquartile range 73.4 to 77.2; 55% women; 50% APOEε4 carriers) were examined in 2014-2016 and 2019-2021 with [11C]PBR28-PET to measure neuroinflammation and [11C]PiB-PET to measure Aβ. [11C]PBR28 and [11C]PiB standardized uptake value ratios (SUVr) were quantified for a cortical composite region using cerebellar grey matter as the reference region. Associations between [11C]PBR28 and [11C]PiB SUVr at baseline and follow-up, and the change in [11C]PBR28 and [11C]PiB SUVr during the follow-up were analysed with linear models adjusted for age, sex and TSPO genotype. The analyses were also stratified by baseline Aβ-positivity (cut-off for positivity [11C]PiB SUVR=1.5). An increase in neuroinflammation ([11C]PBR28 SUVr) was associated with an increase in Aβ accumulation during the 5-year follow-up in the total study population (β=2.95, P=0.002), and in Aβ positive (β=2.89, P=0.04) and negative (β=1.71, P=0.04) individuals. Baseline neuroinflammation did not predict follow-up Aβ binding (β=0.74, P=0.71), or the change in Aβ accumulation during the follow-up (β=0.35, P=0.74) in the total study population. Our results suggest that neuroinflammation associated with Aβ accumulation in older individuals regardless of their Aβ status and that neuroinflammation may drive Aβ accumulation in aging.
- Open Access
- 9 January 2026
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 18 (1)
Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer’s disease
Alzheimer’s disease (AD) is the most common neurodegenerative disorder, affecting millions worldwide. The clinical presentation of AD is heterogenous
- 9 January 2026
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 18 (1)
Open AccessClinical translation of fluid, imaging, and digital biomarkers for Alzheimer’s disease
Alzheimer’s disease (AD) is the most common neurodegenerative disorder, affecting millions worldwide. The clinical presentation of AD is heterogenous
- Open Access
- 4 December 2025
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 18 (1)
Longitudinal biomarker studies in human neuroimaging: capturing biological change of Alzheimer’s pathology
Despite extensive research, open questions about the biological underpinnings of Alzheimer’s disease (AD) remain. Neuroimaging biomarkers based on positron emission tomography (PET) and magnetic resonance imaging (MRI) offer in vivo insights into these complex biological changes and interactions. However, most evidence to date comes from cross-sectional studies, limiting our understanding of disease progression. Longitudinal studies enable the investigation of biological changes within individuals, revealing how pathology evolves over time. With this review, we provide an overview of how longitudinal imaging biomarker studies have advanced the field and how they can contribute to future research. We highlight longitudinal biomarker studies that have provided critical insights into disease trajectories, staging, and individual variability. We further assess longitudinal multimodal studies which have elucidated interactions between AD-specific pathology, amyloid-β and tau, and broader biological changes like neurodegeneration, neuronal dysfunction, vascular disease, and inflammation. Further, we discuss associations of brain changes with symptomatology and clinical outcomes and conclude with challenges and future directions.
- 4 December 2025
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 18 (1)
Open AccessLongitudinal biomarker studies in human neuroimaging: capturing biological change of Alzheimer’s pathology
Despite extensive research, open questions about the biological underpinnings of Alzheimer’s disease (AD) remain. Neuroimaging biomarkers based on positron emission tomography (PET) and magnetic resonance imaging (MRI) offer in vivo insights into these complex biological changes and interactions. However, most evidence to date comes from cross-sectional studies, limiting our understanding of disease progression. Longitudinal studies enable the investigation of biological changes within individuals, revealing how pathology evolves over time. With this review, we provide an overview of how longitudinal imaging biomarker studies have advanced the field and how they can contribute to future research. We highlight longitudinal biomarker studies that have provided critical insights into disease trajectories, staging, and individual variability. We further assess longitudinal multimodal studies which have elucidated interactions between AD-specific pathology, amyloid-β and tau, and broader biological changes like neurodegeneration, neuronal dysfunction, vascular disease, and inflammation. Further, we discuss associations of brain changes with symptomatology and clinical outcomes and conclude with challenges and future directions.
- Open Access
- 15 February 2024
- Published by Elsevier in Neurobiology of Disease
- Vol. 192, 106439
Cognitively healthy APOE4/4 carriers show white matter impairment associated with serum NfL and amyloid-PET
- 15 February 2024
- Published by Elsevier in Neurobiology of Disease
- Vol. 192, 106439
Open AccessCognitively healthy APOE4/4 carriers show white matter impairment associated with serum NfL and amyloid-PET
- Open Access
White matter integrity and its association with amyloid-PET and serum NfL in healthy APOE4 homozygotes, heterozygotes and non-carries
Except for aging, APOE ε4 allele ( APOE4 ) is the most important risk factor for sporadic Alzheimer’s disease. APOE4 carriers may have reduced capacity to recycle lipids, resulting in reduced white matter integrity. Here, we evaluated if white matter impairment measured by diffusion tensor imaging (DTI) differs between healthy individuals with different number of APOE4 alleles and if white matter impairment associates with brain beta-amyloid (Aβ) load and serum levels of neurofilament light chain (NfL). We studied 96 participants ( APOE4/4 , N = 20; APOE4/3 , N = 39; APOE3/3 , N = 37; mean age 70.7 (SD 5.22) years, 63% females) with brain MRI including a DTI sequence (N = 96), Aβ-PET (N = 89) and a venous blood sample for serum NfL concentration measurement (N = 88). Fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD) and axial diffusivity (AxD) in six a priori -selected white matter regions-of-interest (ROIs) were compared between the groups using ANCOVA, with sex and age as covariates. A voxel-weighted average of FA, MD, RD and AxD was calculated for each subject, and correlations with Aβ-PET and NfL levels were evaluated. APOE4/4 carriers exhibited higher MD and higher RD in the body of corpus callosum than APOE4/3 (p = 0.0053 and p = 0.0049, respectively) and APOE3/3 (p = 0.026 and p = 0.042). APOE4/4 carriers had higher AxD than APOE4/3 (p = 0.012) and APOE3/3 (p = 0.040) in the right cingulum adjacent to cingulate cortex. In the total sample, composite MD, RD and AxD positively correlated with cortical Aβ load (r = 0.26 to 0.33, p < 0.013 for all) and with serum NfL concentrations (r = 0.31 to 0.36, p < 0.0028 for all). In conclusion, reduced white matter integrity was detected in cognitively unimpaired APOE4/4 homozygotes compared to APOE4/3 and APOE3/3 carriers and reduced white matter integrity correlated with biomarkers of Alzheimer’s disease and neurodegeneration. White matter impairment seems to be an early phenomenon in the Alzheimer’s disease pathologic process in APOE4/4 homozygotes. Highlights: Cognitively normal elderly APOE4 homozygotes showed impaired white matter integrity APOE4 homozygotes showed higher diffusivity in corpus callosum and right cingulum MD, RD and AxD correlate with amyloid load assessed by PET in APOE4 carriers MD, RD and AxD correlate with serum neurofilament light chain in APOE4 carriers White matter impairment may be an early phenomenon in the AD pathologic process
Open AccessWhite matter integrity and its association with amyloid-PET and serum NfL in healthy APOE4 homozygotes, heterozygotes and non-carries
Except for aging, APOE ε4 allele ( APOE4 ) is the most important risk factor for sporadic Alzheimer’s disease. APOE4 carriers may have reduced capacity to recycle lipids, resulting in reduced white matter integrity. Here, we evaluated if white matter impairment measured by diffusion tensor imaging (DTI) differs between healthy individuals with different number of APOE4 alleles and if white matter impairment associates with brain beta-amyloid (Aβ) load and serum levels of neurofilament light chain (NfL). We studied 96 participants ( APOE4/4 , N = 20; APOE4/3 , N = 39; APOE3/3 , N = 37; mean age 70.7 (SD 5.22) years, 63% females) with brain MRI including a DTI sequence (N = 96), Aβ-PET (N = 89) and a venous blood sample for serum NfL concentration measurement (N = 88). Fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD) and axial diffusivity (AxD) in six a priori -selected white matter regions-of-interest (ROIs) were compared between the groups using ANCOVA, with sex and age as covariates. A voxel-weighted average of FA, MD, RD and AxD was calculated for each subject, and correlations with Aβ-PET and NfL levels were evaluated. APOE4/4 carriers exhibited higher MD and higher RD in the body of corpus callosum than APOE4/3 (p = 0.0053 and p = 0.0049, respectively) and APOE3/3 (p = 0.026 and p = 0.042). APOE4/4 carriers had higher AxD than APOE4/3 (p = 0.012) and APOE3/3 (p = 0.040) in the right cingulum adjacent to cingulate cortex. In the total sample, composite MD, RD and AxD positively correlated with cortical Aβ load (r = 0.26 to 0.33, p < 0.013 for all) and with serum NfL concentrations (r = 0.31 to 0.36, p < 0.0028 for all). In conclusion, reduced white matter integrity was detected in cognitively unimpaired APOE4/4 homozygotes compared to APOE4/3 and APOE3/3 carriers and reduced white matter integrity correlated with biomarkers of Alzheimer’s disease and neurodegeneration. White matter impairment seems to be an early phenomenon in the Alzheimer’s disease pathologic process in APOE4/4 homozygotes. Highlights: Cognitively normal elderly APOE4 homozygotes showed impaired white matter integrity APOE4 homozygotes showed higher diffusivity in corpus callosum and right cingulum MD, RD and AxD correlate with amyloid load assessed by PET in APOE4 carriers MD, RD and AxD correlate with serum neurofilament light chain in APOE4 carriers White matter impairment may be an early phenomenon in the AD pathologic process